Non-Small Cell Lung Cancer (NSCLC) Forecast Report – Designed for Decision Makers and Product Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Growth Rate of the Non-Small Cell Lung Cancer (NSCLC) Market?#_x000D_
In recent times, the size of the non-small cell lung cancer (NSCLC) market has seen substantial growth. It is projected to expand from $20.1 billion in 2024 to $22.35 billion in 2025, yielding a compound annual growth rate (CAGR) of 11.1%. This significant growth during the historic period can be credited to the emergence of immunotherapy, advancements in genomic profiling and precision medicine, wide-scale clinical trials, and initiatives to stop smoking._x000D_
_x000D_
#What Growth Rate Is Forecasted for the Non-Small Cell Lung Cancer (NSCLC) Market by 2029?#_x000D_
The market size for non-small cell lung cancer (NSCLC) is predicted to experience significant expansion in the coming years, reaching a value of $33.29 billion by 2029 with a compound annual growth rate (CAGR) of 10.5%. This anticipated growth in the forecast period is largely due to factors such as the development of combination therapies, the incorporation of artificial intelligence (AI), the proliferation of personalized vaccines, global research collaborations, and a focus on patient-centric care. Trends observed during the forecast period are expected to include the involvement of telemedicine in oncology, advancements in liquid biopsy technologies, progress in diagnostic technologies, the use of minimally invasive surgical procedures, and the implementation of immune checkpoint inhibitors._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp_x000D_
_x000D_
#Which Key Companies Are Shaping the Future of the Non-Small Cell Lung Cancer (NSCLC) Market?#_x000D_
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines_x000D_
_x000D_
#Which Factors Are Driving Demand in the Non-Small Cell Lung Cancer (NSCLC) Industry?#_x000D_
An anticipated rise in the use of tobacco products is set to fuel the expansion of the non-small cell lung cancer (NSCLC) market. It is notable that tobacco consumption which includes smoking, chewing, or snuffing introduces harmful substances such as nicotine and other chemicals into the human body. It is these substances in tobacco smoke that are known to cause damage to deoxyribonucleic acid (DNA) in lung cells, which in turn leads to genetic anomalies and the rampant growth of cancerous cells, including those of non-small cell lung cancer (NSCLC). To put this in context, in October 2024, the US Food and Drug Administration (USFDA) published the 2024 National Youth Tobacco Survey, revealing that a significant 1.1% of all students, approximately 2.25 million students reported current use of tobacco products. Further, the statistics showed 10.1% of high school students (around 1.58 million) and 5.4% of middle school students (about 640,000) were tobacco users. Adding to this, 2.8% of students (around 760,000) reported the current use of any tobacco product that can be ignited, while a slightly higher figure of 3.0% (or about 840,000) were reported as using multiple tobacco products. Lastly, such a growing rate of tobacco consumption is seen as a major driver in the growth of the non-small cell lung cancer (NSCLC) market. Rising levels of air pollution, known for causing harmful effects to health, are being linked to increased cases of Non-Small Cell Lung Cancer (NSCLC), and this is expected to stimulate growth within the NSCLC market. Air pollution comprises harmful substances, usually in gas or particle form, within the Earth’s atmosphere, and these have a detrimental impact on human health. This pollution increases the likelihood of non-small lung cancer by causing inflammation and damage to the DNA of the lung cells, prompting the formation of cancerous tumors. For instance, in June 2023, the World Health Organization recorded that air and household pollution were linked to 7 million premature deaths annually. Moreover, about 2.4 billion people are at risk from harmful household air pollution, which result from using polluting open fires for cooking, powered by kerosene, biomass, and coal. Adding to this concern, the World Bank estimated in September 2022 that health harm caused by air pollution would total around $8.1 trillion annually, equating to a significant 6.1% of global GDP. As such, rising air pollution levels are expected to drive growth in the non-small cell lung cancer (NSCLC) market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp_x000D_
_x000D_
#How Is the Non-Small Cell Lung Cancer (NSCLC) Market Segmented by Several Divisions?#_x000D_
The non-small cell lung cancer (NSCLC) market covered in this report is segmented –_x000D_
_x000D_
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types_x000D_
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies_x000D_
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels_x000D_
_x000D_
Subsegments:_x000D_
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma_x000D_
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma_x000D_
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma_x000D_
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma_x000D_
_x000D_
#What are the Emerging Market Trends Driving the Growth of the Non-Small Cell Lung Cancer (NSCLC) Industry?#_x000D_
Significant business entities in the non-small cell lung cancer (NSCLC) sector are striving for a competitive advantage by focusing on the development of various treatment pathways, like monotherapy treatments. Monotherapy refers to the employment of a single drug or therapy for a medical condition, relying on only one method or therapeutic strategy instead of multiple combined interventions. For example, Novartis AG, a pharmaceutical firm based in Switzerland, was granted permission by the European Commission (EC), a governing entity in Belgium, for the utilization of Tabrecta (capmatinib) in June 2022. The approval was for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) bearing METex14 skipping mutations, who had already underwent previous treatment. This sanction offers a new targeted treatment alternative for patients afflicted with advanced NSCLC in Europe. The mutations responsible for MET exon 14 (METex14) skipping make it the most sought-after targeted treatment for advanced NSCLC._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Regions Are Driving Growth in the Non-Small Cell Lung Cancer (NSCLC) Market?#_x000D_
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the non-small cell lung cancer (nsclc) market, and how is it changing globally?_x000D_
2. Who are the major companies in the non-small cell lung cancer (nsclc) market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the non-small cell lung cancer (nsclc) market right now?_x000D_
4. Which products or customer segments are growing the most in the non-small cell lung cancer (nsclc) market?_x000D_
5. What factors are helping or slowing down the growth of the non-small cell lung cancer (nsclc) market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
